Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by CCAbbott888on Apr 25, 2019 4:04pm
143 Views
Post# 29671379

RE:RE:Whatever your decision is, you should use the rights offer

RE:RE:Whatever your decision is, you should use the rights offer
StockReddy wrote: After the record date where it will trade? based on that I will sell some of my shares and buy the rights, any thoughts?

stockReddy

I don't know what the sp will be after the record date (or the rights offer).

Let say that the rights offer is fully excercised =$75M.

So Prometic willl have only $10M debt, $150M (=75+75) in cash position, few significant catalysts at H2 2019 (2 Lazard deals, BLA re-submission, Nasdaq listing, starting As p3 trial, 2 placebo controlled p2 trials etc.)

if it trades at 1.521 cents, the market cap would be $380M (25Bx $0.1521)
if it trades at 2 cents, the market cap would be $500M
if it trades at 3 cents, the market cap would be $750M (which was the sp level before April 1 PR, I think)

Imo, the chance of it's trading at 1.521 cents or lower post rights offer is low, unless the good new does not materialize in due time and that there's further delays of the BLA resubmission.  Hope that this helps. CC


Bullboard Posts